Krystal Biotech Inc. (KRYS)
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?
Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is the Options Market Predicting a Spike in Krystal Biotech Stock?
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
Krystal Biotech Stock Soars 16% in Three Months: Here's Why
KRYS shares climb 16% in three months as Vyjuvek revenues jump 32%, pipeline programs advance and a nearly $1B cash pile fuels confidence.
Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Krystal Biotech: Vyjuvek Is Not The Primary Asset
Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow and 95% gross margins since FDA approval. KRYS is rated Buy, justified by a robust pipeline—especially oncology flagship KB707—and a $1B cash position supporting R&D without dilution risk. VYJUVEK's international rollout and pipeline catalysts could drive annual net income to $1.8–$2.9B, with forward PE potentially as low as 2.9–4.6.
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
KRYS shares jump after a Q1 beat as Vyjuvek fuels 32% revenue growth, strong uptake and global expansion, with pipeline catalysts lined up through 2026.
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.2 per share a year ago.
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
